Abstract
Purpose: Knee osteoarthritis (OA) affects an estimated 14 million adults in the US, but no disease modifying osteoarthritis drugs (DMOADs) that slow or stop disease progression have been approved to date. The absence of MRI screening prior to enrolling patients to clinical trials may be a contributing factor to failure of such trials due to possible inclusion of participants with safety signals such as existing pathology that that are indicative of a high-risk of OA progression or joint collapse, and as such would not be amenable by any pharmacologic DMOAD approaches.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
